GridAI Technologies Faces Nasdaq Noncompliance Over Delayed 10-K

The latest update is out from GridAI Technologies ( (GRDX) ).

On April 22, 2026, GridAI Technologies Corp. received a notice from Nasdaq’s Listing Qualifications Department that it was not in compliance with listing rules because it had not filed its Form 10-K for the year ended Dec. 31, 2025. The company attributed the delay to complex accounting and information review related to its recent acquisition of Grid AI Corp., and it said it intends to complete the filing as soon as possible.

GridAI has until June 22, 2026, to submit a plan to regain compliance, and Nasdaq may grant it up to Oct. 12, 2026, to resolve the delinquency if the plan is accepted. Failure to secure Nasdaq’s approval could lead to a hearings panel process and ultimately threaten the company’s continued listing, underscoring heightened operational and regulatory risk for shareholders amid the ongoing integration of its new grid software business.

More about GridAI Technologies

GridAI Technologies Corp., formerly Entero Therapeutics, Inc., is a diversified technology and life sciences company listed on Nasdaq under the ticker GRDX. It operates through two main businesses: energy orchestration and grid optimization software solutions delivered via its Grid AI Corp. subsidiary, and legacy biopharmaceutical development centered on Adrulipase for treating exocrine pancreatic insufficiency.

Based in Boca Raton, Fla., the company’s dual focus spans advanced grid software services for the energy sector and drug development activities targeting gastrointestinal disorders. This hybrid model positions GridAI at the intersection of clean energy technology and specialized life sciences, serving both utility-scale infrastructure customers and patients with pancreatic enzyme deficiencies.

Average Trading Volume: 117,576

Technical Sentiment Signal: Sell

Current Market Cap: $7.63M

See more data about GRDX stock on TipRanks’ Stock Analysis page.